Baltimore, Maryland, United States The leading representative office of defined VC is situated in the Baltimore. The company was established in North America in United States.
This organization was formed by Kevin Rakin, Matt Zuga, Matt Zuga.
Speaking about the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2017. The top amount of exits for fund were in 2019. The fund is generally included in less than 2 deals every year. This HighCape Partners works on 16 percentage points less the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 5 - 10 millions dollars.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the HighCape Partners, startups are often financed by MVM Life Science Partners, Connecticut Innovations, XSeed Capital. The meaningful sponsors for the fund in investment in the same round are MVM Life Science Partners, Connecticut Innovations, Stonehenge Capital. In the next rounds fund is usually obtained by MVM Life Science Partners, Springfield Investments, Robert Bosch Venture Capital.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Wellness, Fitness. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Zipline Medical, Cybrexa Therapeutics, Aziyo Biologics
| Fund Name | Location |
| AltCity | Beirut, Beyrouth, Lebanon |
| Amerihealth | - |
| Break Trail Ventures | Boulder, Colorado, United States |
| Bryan Garnier & Co | France, Ile-de-France, Paris |
| Cobalt Networks | California, Mountain View, United States |
| Forum Equity Partners | Canada, Ontario, Toronto |
| Gabelhorn Investment | Central, Central Region, Singapore |
| Hydra Ventures | - |
| InnoSpring | China, Shanghai |
| Ironfire Ventures | China, Hong Kong, Hong Kong Island |
| Jollychic | China, Hangzhou, Zhejiang |
| Lightspeed India Partners | Delhi, India, New Delhi |
| Novotech Investments | Newcastle upon Tyne, North East, United Kingdom |
| Praxis Capital Partners | - |
| Revera Home Health Business | - |
| Seoul Business Agency | Seoul, Seoul-t'ukpyolsi, South Korea |
| Stone Ventures | United Kingdom, Worcester, Worcestershire |
| The Worldbeat Center | California, San Diego, United States |
| Tranquility Capital | Lidköping, Sweden, Vastra Gotaland |
| Women's World Banking | New York, New York, United States |
Discover 4 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Modifi Bio | $4M | 16 Oct 2023 | New Haven, Connecticut, United States | ||
Modifi Bio | $6M | 28 Jul 2022 | New Haven, Connecticut, United States | ||
Wellinks | $25M | 03 Nov 2021 | New Haven, Connecticut, United States | ||
Cybrexa Therapeutics | $25M | 10 Mar 2021 | New Haven, Connecticut, United States | ||
Flyp Nebulizer | $4M | 27 Sep 2019 | Fairfield, Connecticut, United States | ||
Wellinks | $14M | 26 Sep 2019 | New Haven, Connecticut, United States | ||
Cybrexa Therapeutics | $13M | 21 Jun 2019 | New Haven, Connecticut, United States | ||
Cheetah Medical | $11M | 12 Sep 2017 | Newton, Massachusetts, United States | ||
Cybrexa Therapeutics | $6M | 16 Jun 2017 | New Haven, Connecticut, United States |
– Cybrexa Therapeutics from New Haven develops a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform.
– The company completed its $25m Series B financing.
– Backers included HighCape Capital and new investor Elm Street Ventures.
– The new investment will be aimed at planned advancement of its lead candidate CBX-12 (alphalex™-exatecan) into the clinic.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Modifi Bio | $4M | 16 Oct 2023 | New Haven, Connecticut, United States | ||
Modifi Bio | $6M | 28 Jul 2022 | New Haven, Connecticut, United States | ||
Wellinks | $25M | 03 Nov 2021 | New Haven, Connecticut, United States | ||
Cybrexa Therapeutics | $25M | 10 Mar 2021 | New Haven, Connecticut, United States | ||
Flyp Nebulizer | $4M | 27 Sep 2019 | Fairfield, Connecticut, United States | ||
Wellinks | $14M | 26 Sep 2019 | New Haven, Connecticut, United States | ||
Cybrexa Therapeutics | $13M | 21 Jun 2019 | New Haven, Connecticut, United States | ||
Cheetah Medical | $11M | 12 Sep 2017 | Newton, Massachusetts, United States | ||
Cybrexa Therapeutics | $6M | 16 Jun 2017 | New Haven, Connecticut, United States |
